BackGenetic Technologies Overview

Genetic Technologies Other Current Assets

Track Genetic Technologies's other current assets ($340K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$341746.00
1859.55% YoYΔ $324306.00 vs prior year quarter

Peer average

Loading

Genetic Technologies Other Current Assets History

Loading

Genetic Technologies vs. peers: Other Current Assets Comparison

Loading

Genetic Technologies Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Genetic Technologies (GENE) FAQ

Genetic Technologies's other current assets stands at $340K as of June 2024. That compares with $17K in the prior-year period — up 1859.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Genetic Technologies reported $340K in other current assets versus $17K a year earlier — a 1859.6% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $17K in the prior-year period — up 1859.6% year over year. Sustained growth in other current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Genetic Technologies's other current assets evolved across reporting periods, while the comparison chart places GENE next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current assets is commonly used to spot outliers. Genetic Technologies's reading of $340K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.